Zepbound/Mounjaro are approved only for people age 18 and older
[DOI] [PMC free article] [PubMed] [Google Scholar] 59.Williams E., Rudowitz R., Bell C
It puts retatrutide in the same conversation as tirzepatide, which won an FDA sleep-apnea indication in 2024 on similar AHI reductions except retatrutide is reaching these numbers on the back of substantially larger weight loss
But Koliwad who holds UCSFs Grodsky/JAB and Woeber-Mount Zion Distinguished Professorships says the latest treatments really might be the solution some patients have been hoping for
A nested casecontrol design is efficient for evaluating relatively uncommon outcomes (I.e.,substance use disorder) within a large cohort and supports clear temporality between exposure and outcome through index-date anchoring and matching
First, the activity of DPP4 was determined and sitagliptin dramatically suppressed the elevation of DPP4 activity stimulated by TNF/LPS or recombinant human DPP4 (hDPP4) protein (Fig